ArticleACS omega2026
Structure-Based Virtual Screening and
Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Serine/threonine kinase 3 (STK3) is a core kinase in the Hippo signaling pathway that regulates cell proliferation, differentiation, and apoptosis. Dysregulation of this pathway is linked to various cancers and immune disorders, emphasizing STK3 as a promising therapeutic target for diseases that involve abnormal cell growth. Despite their therapeutic relevance, only a limited number of potent STK3 inhibitors have been reported, likely due to the difficulty in designing molecules that can bind tightly to the ATP-binding site of STK3. Using the 2-(2-amino-5-phenylpyrimidin-4-yl)-5-methoxyphenol (APPP) scaffold identified through virtual screening, we discovered a series of novel, potent STK3 inhibitors with half-maximal inhibitory concentration (IC
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.